ImmuPharma Investor Relations Material
Latest events
H2 2024
19 May, 2025
H1 2024
9 Sep, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ImmuPharma plc
Access all reports
ImmuPharma plc is a pharmaceutical company focused on the research, development, and commercialization of novel peptide-based drugs. The company specializes in therapies for autoimmune and inflammatory diseases, with activities spanning early-stage discovery through to clinical development. Its research is supported by collaborations with scientific institutions and licensing partnerships. The company is headquartered in London, United Kingdom, and its shares are listed on the AIM.
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
IMM
Country
🇬🇧 United Kingdom